🧾 What This Document Is

This is a Form 6-K, a report foreign companies like NeuroSense file with the SEC to share major news with U.S. investors. Think of it as a "special update" that includes a press release. Here, NeuroSense is reporting its 2025 financial results and giving a crucial update on its drug development progress, especially for its ALS treatment, PrimeC. 👉 This filing is a snapshot of where the company stands right now—its clinical successes and its financial runway.

🏢 What The Company Does

In simple terms, NeuroSense is a biotech startup trying to develop new drugs for devastating brain diseases like ALS (Lou Gehrig's disease) and Alzheimer's. Their lead drug, PrimeC, is designed to slow the progression of ALS. They don't have a product on the market yet; they are a "clinical-stage" company, meaning they're spending money on research and testing to prove their drugs work and are safe. This is a high-risk, high-reward business model common in biotech.

🧪 The Clinical Story: PrimeC in ALS

This is the most important part of the update. Their drug PrimeC has completed mid-stage (Phase 2b) trials, and the results were very promising.

• The Big News: The trial showed a 65% reduction in the risk of death for patients taking PrimeC and a median survival advantage of over 14 months. That's a huge potential benefit in a disease with very few treatment options.
• Validation: These results were published in the prestigious medical journal JAMA Neurology, which adds significant credibility.
• Next Step: Because the Phase 2b results were positive, the U.S. FDA cleared them to start a large, final Phase 3 trial called PARAGON. This is the last major hurdle before applying to sell the drug.

🌍 Beyond ALS: Alzheimer's Potential

NeuroSense is also testing PrimeC in Alzheimer's disease. They reported early "signals of biological activity" and positive changes in key biomarkers linked to Alzheimer's. While much earlier in development than the ALS program, this shows the potential for their drug to help with other major neurodegenerative diseases.

💰 Financial Snapshot: The Cash Runway

This is the critical reality check for a pre-revenue biotech. All their spending is on R&D and admin, so they operate at a loss.

• 2025 Net Loss: $11.1 million, up slightly from 2024.
• Cash on Hand (as of Dec 31, 2025): $0.166 million. This is an extremely low amount of cash, indicating the company urgently needs to raise more money soon to fund its operations and expensive Phase 3 trial. 👉 This is a major risk factor. The company's survival depends on securing new funding.

🔮 What's Next: Upcoming Milestones

The company has a busy schedule ahead, focusing on turning its promising data into a marketable drug.

• Q2 2026: A planned meeting with Health Canada (Canada's FDA) to discuss a path to approval there.
• 2026: Readouts from additional biomarker studies and the Alzheimer's Phase 2 study.
• Ongoing: Preparations to begin the pivotal Phase 3 PARAGON trial in ALS.

⚖️ The Big Picture: Strengths vs. Risks

👍 Strengths:

• Powerful Clinical Data: The >14-month survival benefit is a standout result that could make PrimeC a best-in-class treatment if confirmed in Phase 3.
• Clear Path Forward: FDA clearance for Phase 3 and a plan for Canadian regulators show a defined roadmap.
• Peer-Reviewed Validation: Publication in JAMA Neurology strengthens scientific credibility.

⚠️ Risks:

• Looming Cash Crunch: With only ~$166k in cash, they need to raise significant capital immediately. This could lead to dilution for existing shareholders or, if unsuccessful, could halt operations.
• The Phase 3 Hurdle: The Phase 3 trial is large, expensive, and will take years. There's no guarantee it will confirm the Phase 2 results.
• Regulatory Uncertainty: Even with good data, regulatory approval is never guaranteed.

🧠 The Analogy

NeuroSense is like a promising startup that just built an incredible prototype (PrimeC's Phase 2 data). They've gotten green lights from key inspectors (FDA clearance) and glowing reviews from industry experts (JAMA Neurology). Now, they need to build a full-scale factory (run the Phase 3 trial) to mass-produce it. The catch? Their bank account is nearly empty, so they need investors to fund the factory build-out before they can sell a single product.

📇 Key Contacts & People

• Alon Ben-Noon: Chief Executive Officer (CEO)
• Company Contact: [email protected] (for shareholder requests and investor relations)
• Investor Relations Website: https://neurosense.investorroom.com/sec-filings

🧩 Final Takeaway

NeuroSense has highly promising clinical data for its ALS drug, PrimeC, with a major survival benefit that positions it as a potential breakthrough therapy. However, the company is in a race against time, as it has virtually no cash left and must secure substantial new funding to execute its next crucial phase of development. The upcoming Phase 3 trial results will be the ultimate make-or-break moment.